Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Pancreatic cancer (PC) is one of the most common malignancies and also a leading cause of cancer-related mortality worldwide. Many studies have shown that epidermal growth factor receptor (EGFR) is highly expressed in PC, which provides a potential target for PC treatment. However, EGFR inhibitors u...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Shihui, Zheng, Hailun, Ye, Jinyao, Huang, Huirong, Zhou, Bin, Yao, Qing, Lin, Guangyong, Zhang, Hailin, Kou, Longfa, Chen, Ruijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017486/
https://www.ncbi.nlm.nih.gov/pubmed/33815107
http://dx.doi.org/10.3389/fphar.2021.625084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017486/
https://www.ncbi.nlm.nih.gov/pubmed/33815107
http://dx.doi.org/10.3389/fphar.2021.625084

Ejemplares similares